SIHUAN PHARMACEUTICAL HOLDINGS GROUP LTD. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.61 HKD | 0.00% |
|
+7.02% | -6.15% |
| May. 02 | Sihuan Pharmaceutical Unit's Lung Cancer Drug NDA Accepted by NMPA, Stocks Shoot Over 10% | MT |
| Apr. 25 | Sihuan Pharma Unit Wins Bid to Supply Insulin Products to Chinese Government | MT |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Capitalization 1 | 7,867 | 6,533 | 11,251 | 7,828 | 5,512 | 5,220 | - |
| Enterprise Value (EV) 1 | 7,867 | 6,533 | 11,251 | 7,828 | 5,512 | 5,220 | 5,220 |
| P/E ratio | -2.86 x | 13 x | 27.5 x | -4.09 x | -114 x | 56.2 x | 14.1 x |
| Yield | 2.05% | 2.03% | 1.08% | - | - | 8.89% | 8.89% |
| Capitalization / Revenue | 2.73 x | 2.65 x | 3.42 x | - | 2.96 x | 1.91 x | 1.64 x |
| EV / Revenue | 2.73 x | 2.65 x | 3.42 x | - | 2.96 x | 1.91 x | 1.64 x |
| EV / EBITDA | - | 6.34 x | 10.6 x | - | -35.8 x | -48.8 x | 39.5 x |
| EV / FCF | - | - | - | - | - | - | - |
| FCF Yield | - | - | - | - | - | - | - |
| Price to Book | 0.82 x | 0.71 x | 1.35 x | - | - | 1.08 x | 1.1 x |
| Nbr of stocks (in thousands) | 9,465,682 | 9,465,682 | 9,329,999 | 9,329,999 | 9,329,999 | 9,281,566 | - |
| Reference price 2 | 0.8311 | 0.6902 | 1.206 | 0.8390 | 0.5908 | 0.5624 | 0.5624 |
| Announcement Date | 3/24/20 | 3/23/21 | 3/29/22 | 3/24/23 | 3/28/24 | - | - |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Net sales 1 | 2,887 | 2,464 | 3,291 | - | 1,861 | 2,733 | 3,186 |
| EBITDA 1 | - | 1,031 | 1,065 | - | -153.9 | -107 | 132 |
| EBIT 1 | 1,517 | 787.1 | 763.9 | - | -193.2 | -305 | -74 |
| Operating Margin | 52.53% | 31.94% | 23.21% | - | -10.39% | -11.16% | -2.32% |
| Earnings before Tax (EBT) 1 | -2,467 | 765.8 | 486 | - | -161.3 | -589 | -385 |
| Net income 1 | -2,753 | 473.4 | 416.5 | -1,915 | -54.02 | 107 | 337 |
| Net margin | -95.37% | 19.21% | 12.65% | - | -2.9% | 3.92% | 10.58% |
| EPS 2 | -0.2910 | 0.0530 | 0.0439 | -0.2052 | -0.005200 | 0.0100 | 0.0400 |
| Free Cash Flow | - | - | - | - | - | - | - |
| FCF margin | - | - | - | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - |
| Dividend per Share 2 | 0.0170 | 0.0140 | 0.0130 | - | - | 0.0500 | 0.0500 |
| Announcement Date | 3/24/20 | 3/23/21 | 3/29/22 | 3/24/23 | 3/28/24 | - | - |
1CNY in Million2CNY
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - | - | - |
| Net Cash position | - | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - |
| Free Cash Flow | - | - | - | - | - | - | - |
| ROE (net income / shareholders' equity) | -24.9% | 5.04% | 4.77% | - | - | 2.3% | 6.7% |
| ROA (Net income/ Total Assets) | -19.7% | 3.7% | 3.03% | - | - | 0.9% | 2.7% |
| Assets 1 | 14,007 | 12,808 | 13,769 | - | - | 11,889 | 12,481 |
| Book Value Per Share 2 | 1.010 | 0.9700 | 0.8900 | - | - | 0.5200 | 0.5100 |
| Cash Flow per Share 2 | 0.1500 | - | 0.0700 | - | - | 0.0400 | 0.0700 |
| Capex 1 | 590 | 581 | 767 | - | - | 350 | 350 |
| Capex / Sales | 20.43% | 23.56% | 23.32% | - | - | 12.81% | 10.99% |
| Announcement Date | 3/24/20 | 3/23/21 | 3/29/22 | 3/24/23 | 3/28/24 | - | - |
1CNY in Million2CNY
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
0.61
Average target price
-
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -6.15% | 724M | |
| +31.52% | 690B | |
| +24.35% | 546B | |
| -5.21% | 358B | |
| +17.02% | 323B | |
| +5.01% | 287B | |
| +13.43% | 235B | |
| +4.35% | 199B | |
| -10.35% | 195B | |
| +3.98% | 161B |
- Stock Market
- Equities
- 460 Stock
- Financials Sihuan Pharmaceutical Holdings Group Ltd.